Power Arginine Injection (L-Arginine Hydrochloride)

Adult administration

Administer 0.2–1g of L-arginine hydrochloride per kg of the patient's weight via slow intravenous infusion for more than 1 hour.

This drug should not be used in patients who are prone to allergic reactions. Furthermore, individuals with a history of hypersensitivity or allergic reactions to this medication or its components should not be administered this drug. Patients with severe acidosis or those with very low blood pressure should also avoid using this medication. It is contraindicated in patients with diseases related to nitric oxide production or those who have experienced myocardial infarction, as well as in patients with arginase deficiency. Use in patients with severe liver dysfunction or moderate renal impairment, kidney diseases, or anuria (almost no urination) should be approached with caution. Caution is also advised in uremic patients who may have elevated potassium levels and in those with electrolyte imbalances. For patients with bronchial asthma, symptoms may temporarily worsen, requiring attention. Rapid administration may cause nausea, vomiting, skin erythema, headache, numbness, or venous irritation. Very rarely, serious side effects such as hypotension, severe allergic reactions, and hyperkalemia can occur. Additionally, cases of hyperammonemia, skin ulcers, and increased blood urea have been reported. If an allergic reaction occurs during administration, antihistamines should be used, and blood pressure should be continuously monitored for 24 hours during and after administration. If hyperammonemia does not improve, concurrent treatments such as peritoneal dialysis, hemodialysis, or exchange transfusion should be considered. Excessive administration of the hydrochloride component may lead to hyperchloremic acidosis, so pH levels of the blood should be periodically monitored during administration. Caution is needed for women who are pregnant or may become pregnant, and the drug should be administered cautiously only when the therapeutic benefits outweigh the risks; breastfeeding women should avoid administration or stop breastfeeding during treatment if necessary. Overdosage may cause temporary metabolic acidosis and hyperventilation, which may require correction with alkalinizing agents. If there is redness, swelling, skin necrosis, or ulceration suspected at the intravenous injection site, administration should be discontinued immediately and appropriate care provided. During storage, the solution should not be used if it becomes discolored, cloudy, or precipitated, and products beyond their expiration dates or with damaged packaging should not be used. Keep it out of reach of children, and do not reuse leftover injection solution.

Serious side effects

• Hypotension
• anaphylactic reactions
• severe allergic reactions
• severe hyperkalemia
• skin necrosis
• ulcer formation

Mild side effects

• Nausea
• vomiting
• erythema
• headache
• numbness
• partial venous irritation
• hyperammonemia
• skin ulcers
• increased blood urea
• hypersensitivity

This drug should be stored in a sealed container to prevent air or moisture from entering, and it is important to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will ensure the safety and effectiveness of the medication.

Appearance

A colorless, transparent solution filled in a polypropylene, multilayer film plastic container for injection.

Package unit

100mL/pack